CD19/CD20 Double Knockout Raji/Luciferase Cell Line

Description

CD19/CD20 Double Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphocyte model derived from Raji cells, featuring stable luciferase(Luc) reporter expression and complete knockout of both CD19 and CD20 (MS4A1) surface markers. This cell line maintains characteristic Raji cell morphology and proliferation kinetics while providing sensitive bioluminescence for in vivo tracking. The dual knockout of key B-cell antigens creates a valuable model for studying resistance mechanisms to CD19/CD20-targeted immunotherapies (including CAR-T and monoclonal antibodies) and developing alternative treatment strategies. With stable luciferase expression maintained at low passages (<P20), this line enables quantitative tumor monitoring in xenograft studies while serving as a platform for investigating antigen escape in B-cell malignancies. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The CD19/CD20 Double Knockout Raji/Luciferase Cell Line is an engineered B-cell lymphoma model featuring complete genetic disruption of both CD19 and CD20 markers alongside stable luciferase reporter integration. This triple-modified system enables quantitative bioluminescence tracking of tumor progression while serving as a critical tool for studying resistance mechanisms to dual-antigen targeted immunotherapies (e.g., CAR-T, bispecific antibodies). Particularly valuable for investigating alternative B-cell signaling pathways and developing next-generation lymphoma treatments, the cell line maintains consistent phenotypic and functional characteristics when cultured in RPMI-1640 with 10% FBS and appropriate antibiotics.